Market Intelligence, Clinical Progress, and High-Purity Reagents for Liver Regeneration, Mitochondrial Medicine, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALR/GFER drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALR/GFER Recombinant Protein (Mature Form) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Preserves sulfhydryl oxidase activity. |
View GFER Products |
| Gene Delivery | ALR/GFER ORF Lentivirus Particles Full-length ORF with/without mitochondrial targeting sequence. For stable hepatocyte lines. |
View GFER Products |
| Benchmark Ab | Anti-ALR (Clone E-11 Reference) Recombinant rabbit monoclonal positive control for Western/IP. |
View GFER Products |
| Validator | ALR/GFER siRNA Set (3 unique sequences) For specific knockdown verification in redox studies. |
View GFER Products |
| Related Target: HGF | Hepatocyte Growth Factor Synergistic liver regeneration pathway; co-receptor c-Met signaling axis. |
View HGF Products |
| Related Target: EGFR | Epidermal Growth Factor Receptor Parallel proliferation pathway in hepatocyte mitogenesis; synergizes in HCC. |
View EGFR Products |
| Related Target: STAT3 | Signal Transducer and Activator of Transcription 3 Downstream mediator of ALR-induced hepatoprotection. |
View STAT3 Products |
| Related Target: BCL2 | B-cell lymphoma 2 Downstream anti-apoptotic partner in ALR-mediated mitochondrial survival. |
View BCL2 Products |
Critical Assay Challenge & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Redox Activity Preservation (Disulfide bond integrity) | HEK293 Expressed with native oxidative folding; >95% purity by SEC-HPLC; Monomeric content verified |
| Mitochondrial vs Secreted Isoform Specificity | Both preprotein (1-205 aa) and mature form (34-205 aa) available; N-terminal sequencing verified |
| Hepatocyte Specificity Validation | Endotoxin Controlled (<0.1 EU/µg) for sensitive primary hepatocyte assays |
| Cross-species Liver Models | Human, Mouse, Rat, and Cynomolgus ALR orthologs with species-specific activity conservation |
| In Vivo Modeling & Ortholog Screening | Human/Mouse/Rat ortholog proteins available with >95% purity and theoretical MW strictly confirmed |
| False Positives in Toxicity Screens | Endotoxin-controlled reagents (<1 EU/ug) and sequence-verified siRNA for target specificity validation |
Live ALR/GFER R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALR/GFER therapeutics is intensifying across dual paradigms: harnessing its regenerative capacity for acute liver failure and inhibiting its anti-apoptotic functions in oncology. While early pipelines focused on recombinant ALR administration for hepatoprotection, the next wave of R&D is targeting its pathological overexpression in solid tumors like Hepatocellular Carcinoma (HCC) through small molecule inhibitors or targeted mAbs that block the ALR-mediated mitochondrial import pathway and its FAD-dependent sulfhydryl oxidase activity. Simultaneously, the shift from traditional growth factor replacement to mitochondrial-targeted redox modulation is driving first-generation recombinant ALR therapies toward chronic metabolic liver diseases (e.g., MASLD) and mitochondrial encephalopathies, employing subcutaneous delivery formulations and tissue-specific targeting technologies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | HepaRegeniX, Academic Consortia | Acute Liver Failure, Post-transplant, Cirrhosis | Redox Activity Assay (Need properly oxidized, endotoxin-free protein) |
| Gene Therapy (AAV) | Early-stage Biotechs | Chronic Hepatitis, Cirrhosis | Expression Validation (Need high-titer Lentivirus for hepatocyte transduction) |
| Small Molecule Activators | Discovery Phase | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Sulfhydryl Oxidase Activity Assay (Need purified ALR for screening) |
| Small Molecule Inhibitors | Preclinical stage entities | Hepatocellular Carcinoma (HCC) | Enzymatic Selectivity Assay (Need sequence-verified intact enzyme) |
| Mitochondrial Targeting | Specialized Research Labs | Mitochondrial Encephalopathy | Subcellular Localization Studies (Need specific isoforms with/without MTS) |
| Targeted mAbs | Preclinical stage entities | Solid Tumors | Epitope Mapping (Need precisely truncated ECD/secreted variants) |